NASDAQ · EMBC

Embecta Corp.

$3.29 +$0.04 (+1.23%) 1D After hours
Session Pulse Overnight session 1 mentions on Fri · 0 bullish / 1 bearish tags No new SEC filings since Mon close its sector ranked 6/11 this week Full pulse →
Charting by TradingView

Key Metrics

$192.81M
Market cap
1.72×
P/E · TTM
$1.04B
Revenue · TTM
$111.90M
Net income
EPS · TTM $1.87
Dividend yield 18.3%
Free cash flow $204.70M
Beta · 1Y 0.72
EBITDA · TTM $212.40M
Gross margin 61.9%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 26
    The stock moved +12.2% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jun 26
  • May 19
    From its Feb 4 high, the share price fell 74%.

    Peak close $11.35 on Feb 4; trough close $2.90 on May 19. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -74%
  • May 5
    The stock moved -57.8% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 5

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$192.81M
Enterprise value$1.33B
Shares outstanding59.3M
52-wk range$2.77 – $15.55
Avg volume · 20D734.1K
Net cash −$1.14B
Book value / share$-10.48
IndustrySurgical & Medical Instruments & Apparatus
ExchangeNASDAQ
About Embecta Corp.
IPO dateMar 21, 2022
Employees1850

Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes.

Wolf Grade COMING SOON

—

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E1.72
P/S0.18
P/FCF0.94
EV/EBITDA6.28
EV/Sales1.28
Graham №—

Profitability

Gross 61.9%
Operating 16.3%
Net 10.7%
FCF 19.6%
ROE / ROIC -16.4% · 21.7%

Financial Health

Current ratio2.46
Quick ratio1.68
Debt / equity-2.12
Debt / EBITDA 6.24
Net cash −$1.14B
Working capital$360.80M

Cash Flow · TTM

Operating CF $213.50M
Capex −$8.80M
Free cash flow $204.70M
Buybacks —
Dividends paid $35.30M
Shareholder yield 18.3%

Piotroski F-Score

6 / 9
Middling fundamentals · 6 of 9 signals passing

Altman Z-Score

—
Insufficient balance-sheet inputs

Graham Number vs Price

—
Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings